Veeva Systems Inc. Website

Veeva Systems Inc.

NYSE-VEEV

Company Overview

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud, a suite of software, data, and analytics solutions, which include Veeva customer relationship management (CRM) and Veeva Medical CRM, Veeva CLM, Veeva CRM MyInsights, Veeva CLM, Veeva CRM Approved Email, Veeva CRM Engage, Veeva Align, Veeva CRM Events Management, Veeva Nitro, Veeva OpenData, Veeva Link, Veeva Network, Veeva Crossix, Veeva Data Cloud, and MyVeeva for Patients; and Veeva Vault, a cloud-based enterprise content and data management applications for managing commercial functions, including sales and marketing, and medical content and communications, as well as research and development functions, such as clinical, regulatory, quality, and safety. It also provides professional and support services in the areas of implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; technical consulting services related to data migration and systems integrations; training on its solutions; and ongoing managed services that include outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

  • Name

    Veeva Systems Inc.

  • CEO

    Peter Gassner

  • Website

    www.veeva.com

  • Sector

    Health Care Technology

  • Year Founded

    2007

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Veeva continues to introduce new applications in areas such as safety and clinical operations to service unmet needs, which support our double-digit growth assumptions.

  • Investing in its AI capabilities allows Veeva to provide additional services, deploy advanced technologies, and bolster switching costs.

  • Venturing outside of life sciences and into new segments expands Veeva’s end markets and opens up new opportunities.

Bears Say

  • Moving its CRM from Salesforce’s platform to its Vault Platform could raise concerns for customers and lower its retention rate.

  • The Iqvia/Salesforce partnership to introduce its own version of life sciences CRM could take away potential new customers from Veeva.

  • New modules or add-ons could show low penetration rate and win less customers compared with previously launched products.

Source: Morningstar Analysis - Nov 21, 2025

What's happening

Nov 5, 2025 - Dec 5, 2025

Veeva Systems Faces Significant Challenges Amidst Earnings Beat

  • Veeva reported Q3 earnings that exceeded analyst expectations, but shares fell sharply due to concerns over CRM performance.
  • Citigroup maintained a Buy rating while lowering its price target after announcing an expanded partnership with Roche Pharmaceuticals.
  • Management changes, including the resignation of Chief Accounting Officer Kristine Diamond, added to investor uncertainty regarding leadership stability.

Over the past month, Veeva Systems Inc. (VEEV) experienced a significant decline of 17.8%. This performance starkly contrasts with the S&P 500's modest gain of 1.3%, resulting in an underperformance of 19% relative to the index. Additionally, VEEV lagged behind the Health Care sector by 23.9%. The downward trend was primarily driven by several bearish events overshadowing its financial results.

On November 21, Veeva announced its Q3 earnings results, reporting an adjusted EPS of $2.04 and revenues reaching $811.2 million—both figures surpassing analyst expectations. Despite this positive news and raised guidance for FY2026 revenue and EPS, shares plummeted over 10% following these announcements due to heightened concerns surrounding CRM performance amid increasing competition and potential demand challenges.

The situation deteriorated further when Citigroup lowered its price target on November 24 after revealing an expanded partnership with Roche Pharmaceuticals for adopting Veeva Vault CRM across Roche’s global organization. Although this initiative aimed at enhancing customer engagement through AI capabilities was viewed as strategic progress, it did not alleviate investor fears about ongoing migration risks associated with their CRM platform.

Additionally, pre-earnings sentiment suffered from management changes within Veeva; Chief Accounting Officer Kristine Diamond announced her resignation effective December 11th without providing reasons or details on succession plans. This contributed to uncertainty around leadership stability during critical operational transitions.

Overall market reactions reflected skepticism towards Veeva's ability to maintain momentum despite solid earnings reports and growth projections due to increased competitive pressures and internal execution challenges leading up to year-end evaluations.

NYSE:VEEV